ZNTL
Zentalis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.99
−2.92%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
Market Cap
$377.74M
MomentumView details →
1D Return
−2.92%
YTD Return
+193.33%
RSI (14)
47.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
Market Cap
$377.74M
RSI (14)
47.8
MomentumView details →
1D Return
−2.92%
YTD Return
+193.33%
SummaryUpdated Jun 1, 2026
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in New York, New York. The company went public in April 2020 and focuses on discovering and developing small molecule therapeutics specifically designed to treat various forms of cancer. Zentalis operates in the highly specialized field of precision oncology, where it develops targeted therapies that aim to disrupt specific molecular pathways involved in cancer cell growth and survival.
Similar companies
Latest newsMore news →